Sanofi (NYSE: SNY) announced that the LixiLan-O Phase III clinical trial met its primary objective in patients with type ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE